A breakthrough in
eliminating solid tumors
A major limitation of adoptive cell immunotherapy is its insufficient therapeutic efficacy, even with the use of genetically modified chimeric antigen receptor (CAR)-T and natural killer (NK) cells.
Our platform enables the production of NK-like cells that effectively eliminate solid tumors, without any genetic modification.
and activating peptide
A peptide-based platform
to generate GAIA NK-like cells
targeting a variety of tumors
GAAAP enables the generation of GAIA NK-like cells that maintain their active state in vivo and specifically target cancer cell-expressed proteins.Core Technology II
GAIA BioMedicine Raised a Total of JPY 650 Million in Series A Round.
Nikkei Biotech ONLINE – GAIA BioMedicine is now developing allogeneic natural killer (NK)-like cell therapy for solid tumors –
Our President & CEO Kazu Kuramori was at the Innate Killer Summit 2019 – Title：GAIA-102 as an NK Cell-Based “Upward Compatible” Modality Over CAR-T-Cell Therapy –
GAIA BioMedicine has released an experimental kit to produce highly activated NK-like cells for research use